baber/WOPTO huggingface dataset:
Patent NZ-545557-A (NZ)
Title: Rigid axle for a vehicle, comprising integrated trailing arms
Inventor: RAMSEY JOHN E
IPC: B60G21/05
Filed: 2004-09-14
Abstract: An air-ride axle/suspension system for a wheeled vehicle is provided. The system includes a pair of pivot bushings for pivotally mounting the system to a frame of the vehicle, pairs of shock absorbers and air springs, and a pair of axle spindle ends for mounting wheels on the system. The improvement includes an integral non-hollow structure, including a pair of arms and a cross member. The pair of arms is transversely spaced relative to the vehicle, with each of the arms extending in a longitudinal direction relative to the vehicle. Each arm includes an upper surface, a lower surface, and an inboard surface extending vertically between the upper and lower surfaces. The cross member extends transversely between the arms and is connected to each one of the arms. The cross member includes a vertically disposed portion and a horizontally disposed portion, with the horizontally disposed portion being connected to the inboard surface of each of the arms between the arm upper and lower surfaces. The pivot bushings, shock absorbers, air springs, and axle spindle ends are mounted on the integral structure, whereby roll forces encountered by the axle/suspension system during vehicle operation are distributed throughout the integral structure to enable the system to achieve roll compliance.
Patent NZ-545580-A (NZ)
Title: Aminoquinoline derivatives and their use as adenosine A3 ligands
Inventor: ARANYI PETER
IPC: C07D215/48
Filed: 2004-07-23
Abstract: Disclosed are compounds of the general formula (I) wherein X stands for -CH2-, -NH-, NR9- or sulphur, oxygen, sulpho or sulphoxy, wherein the rest of the substituents are disclosed within the specification; and their salts, solvates and isomers. Also disclosed is the use of the above compound of general formula (I) for the manufacture of a pharmaceutical composition for the treatment of diseases in development of which the receptor A3 plays a role.
Patent NZ-547837-A (NZ)
Title: Endoparasiticidal agents for topical application
Inventor: KANIKANTI VENKATA-RANGARAO
IPC: A61K9/00
Filed: 2004-11-30
Abstract: Disclosed is a composition, comprising: a) as an active compound a cyclic depsipeptide and/or praziquantel b) a pyrrolidone solvent c) a terpene hydrocarbon as a terpene penetration enhancer. Also disclosed is a process to prepare such compositions and the use of such compositions for controlling endoparasites in non-human animals.
Patent NZ-548964-A (NZ)
Title: Dual cartridge air dryer with oil separator and readily changeable valves
Inventor: SALZMAN MONTE
IPC: B01D53/02
Filed: 2005-02-08
Abstract: An air dryer system including two substantially identical canister-type air dryer units is disclosed. Each includes, in one mode, a first moist air inlet, a first desiccant for drying air, a first dry air outlet, and first means for supplying dry air to a storage facility. The system also includes, in the same mode, a first bleed valve supplying a small portion of the dry air to regenerate a second desiccant, and a first moist air purge valve for dumping moisture collected during regeneration. The system is also operable in an opposite mode, having a second moist air inlet, a second desiccant, a second dry air outlet and second means for supplying air to a storage facility. A second bleed valve supplies a small portion of the dry air to regenerate the first desiccant, and purges moisture through a second moist air purge valve. Located between the moist air inlets and the desiccants are a pair of air-oil separator assemblies, each air-oil separator assembly lying in a housing. Upwardly directed air flows through the housing, strikes a deflector plate, passes through an imperforate centre section and escapes beneath a vertically extending fence and through vents containing a filter medium.
Patent NZ-554610-A (NZ)
Title: Method of treating cellulose fibres under acidic conditions in the presence of carboxymethyl cellulose
Inventor: GRESCHIK THOMAS CHRISTOPHER
IPC: D21C9/10
Filed: 2005-09-28
Abstract: Disclosed is a method of modifying cellulose fibres comprising providing a pulp suspension of cellulose fibres, adding a cellulose derivative (such as carboxymethyl cellulose) during the bleaching of said cellulose fibres to at least one acidic bleaching stage, wherein the pH in the pulp suspension is from about 1 to about 4 and the temperature ranges from about 30 to about 95°C.
Patent NZ-554689-A (NZ)
Title: Hydroxybenzoate salts of metanicotine compounds
Inventor: MUNOZ JULIO A
IPC: A61K31/4406
Filed: 2005-11-09
Abstract: Disclosed is a process for the production of a hydroxybenzoate salt of (4E)-N-methyl-5-(5-isopropoxy-3- pyridinyl)-4-penten-2-amine (hydroxybenzoate salt of E-metanicotine-type compound). Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders can be treated by administering to a patient in need thereof compositions comprising the hydroxybenzoate salt of E-metanicotine-type compound. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
Patent NZ-555858-A (NZ)
Title: Digital indicator
Inventor: AGUGLIA JORGE MIGUEL
IPC: G01D7/00
Filed: 2005-07-18
Abstract: An indicator instrument comprises a display device (20) and a control circuit (30) connected to the display device and arranged for transmitting to the display device signals indicating values measured by a certain type of a measuring device (15) connectable to the control circuit. The display device comprises a plurality of display entities (22, 25, 26, 29) that can be selectively actuated by the control circuit for displaying selected display entities and for leaving invisible not selected display entities of the plurality of display entities. The control circuit comprises a communication device (34) adapted to be connected to an external device (45) configured for setting up the control circuit to selectively actuate the plurality of display entities on the basis of the type of measuring device (15) connectable to the control circuit. A measuring system comprises at least a first indicator instrument as described above and at least a first measuring device (15) connected to the indicator instrument.
Patent NZ-561605-A (NZ)
Title: Papermaking process using enzyme-treated sludge, and products
Inventor: HILL WALTER B
IPC: D21H21/16
Filed: 2002-11-26
Abstract: Disclosed is a method of improving sizing in a paper or paper board product comprising combining a papermaking sludge with an enzyme composition to form an enzyme-treated sludge; combining said enzyme treated sludge with a papermaking pulp to form a treated pulp, forming a paper or paperboard product from said treated pulp, wherein said product has improved sizing compared to the sizing of an identical paper or paperboard product but not having the sludge treated with enzyme composition, wherein said enzyme composition comprises at least one polyamide oligomer and at least one cellulitic enzyme or alternatively a protease, esterase or a lipase.
Patent NZ-562333-A (NZ)
Title: Methods for treating and preventing fibrosis resulting from wound healing using interleukin 21 / interleukin 21R antagonists
Inventor: YOUNG DEBORAH A
IPC: A61K33/242
Filed: 2006-04-13
Abstract: Disclosed is the use of an agent that reduces the level of IL-21 and/or IL-21R in a subject for treating, ameliorating, or preventing fibrosis or a fibrotic condition in the subject, wherein the fibrosis or fibrotic condition is the result of wound healing
Patent NZ-569303-A (NZ)
Title: Water lance assembly for use on a helicopter or tower
Inventor: MACKINNON GRANT
IPC: B05B15/68
Filed: 2006-11-30
Abstract: A water lance assembly (10) for a helicopter (110) including a body frame attachable to a floor of the helicopter, a support frame (112) which in use is located on a first side of the helicopter for supporting a pump (116) which is in fluid communication with a water tank (114) supported by the helicopter, which support frame is releasably attached to the body frame and a water lance supported by the helicopter and located on the other side of the helicopter directly opposite to the first side. The application also discloses a water lance including a lance tube, means for pivotal movement of the lance tube about a longitudinal axis, means for pivotal movement of the lance tube about a horizontal axis, biasing means to return the water lance to a horizontal position and adjustment means to adjust the biasing means to accurately direct the water lance at a desired location.
Patent NZ-571434-A (NZ)
Title: Water dispenser
Inventor: WILSON THOMAS PAUL
IPC: B67D7/58
Filed: 2008-09-18
Abstract: A water dispensing unit comprising: a housing; a reservoir mounted in the housing, the reservoir being adapted to receive water from an external source, the reservoir having an outlet aperture; a pump mounted to the reservoir, the pump having a pump inlet, a pump outlet and a pump chamber, wherein the pump inlet is mounted at the outlet aperture, so that the pump chamber is in open fluid communication with the reservoir; a water filter mounted to the housing, the water filter having a water filter inlet and a water filter outlet, the water filter inlet being in fluid communication with the pump outlet; and a spout mounted on the housing, the spout being in fluid communication with the water filter outlet.
Patent NZ-587179-A (NZ)
Title: Detection of polymorphisms CYP2C19*17 and CYP2C19*3 in CYP2C19 gene related to antiplatelet drug metabolism (e.g. for clopidogrel metabolism)
Inventor: GLADDING PATRICK
IPC: C12Q1/68
Filed: 2009-01-23
Abstract: Discloses a method designed to predict or determine a subject's level of metabolism for a thieonopyridine class antiplatelet agent (for example, the anticoagulant clopidogrel). The method, a SNP detection assay, involves analysing a sample from a subject to determine the presence or absence of the -806C/T polymorphism in the CYP2C19 gene (CYP2C19*17 polymorphism) or 636 G>A polymorphism in the CYP2C 19 gene (CYP2C 19*3 polymorphism). The presence of said polymorphism indicating that the subject has an increased level of metabolism for said thieonopyridine class anti platelet agent.
Patent NZ-588555-A (NZ)
Title: Use of epothilone d in treating tau-associated diseases including alzheimer's disease
Inventor: ALBRIGHT CHARLES F
IPC: A61K31/427
Filed: 2009-04-24
Abstract: Disclosed herein is the use of epothilone D in the manufacture of a medicament, either formulated for intravenous or oral administration, for treating Alzheimer's diseases or a Tau-associated disease in a human patient in need of treatment thereof, wherein the Tau-associated disease is selected from frontotemporal dementia with Parkinsonism linked with chromosome 17 (FTDP-17), progressive supranuclear palsy, corticobasal degeneration, Pick's disease, agyrophilic grain disease, Down syndrome, myotonic dystrophy, Niemann-Pick C disease, dementia pugilistica, Blint disease, and traumatic brain injury.
Patent NZ-593537-A (NZ)
Title: Isoquinoline derivatives and methods of use
Inventor: BAELL JONATHAN BAYLDON
IPC: A01N43/00
Filed: 2009-12-17
Abstract: Disclosed herein are isoquinoline compounds of formula I-a, wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful in the treatment or prevention of a disease or condition caused, exacerbated by or resulting from an excess of, or undesired activation of, platelets in a patient, as such is useful for treating essential thrombocythemia, polycythemia vera, restenosis, perioperative antiplatelet therapy and device-associated thrombi and also small cell lung cancer. Examples of particularly preferred compounds include: 2-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)thiazole-4-carboxylic acid; 5-(3-(4-aminophenoxy)propyl)-2-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)thiazole-4-carboxylic acid; 5-(3-(1H-imidazol-1-yl)propyl)-2-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)thiazole-4-carboxylic acid; 5-((4-(5-amino-4-cyano-1H-pyrazol-3-yl)phenoxy)methyl)-2-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)thiazole-4-carboxylic acid; 2-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-5-(3-(4-(4-cyanothiophen-3-yl)phenoxy)propyl)thiazole-4-carboxylic acid; 5-(3-(4-((1S,2S,5R)-9-aminobicyclo[3.3.1]nonan-2-yl)phenoxy)propyl)-2-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)thiazole-4-carboxylic acid; 6-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3-(3-(4-(5-(2-(dimethylamino)ethoxy)pyridin-2-yl)phenoxy)propyl)picolinic acid; 2-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-5-(3-(4-(3-(dimethylamino)prop-1-ynyl)-2-fluorophenoxy)propyl)-N-hydroxythiazole-4-carboxamide.
Patent NZ-594915-A (NZ)
Title: A method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
Inventor: WONG BING LOU
IPC: A61K35/14
Filed: 2011-04-15
Abstract: Disclosed is a method of making a high temperature-stable and highly purified cross-linked (optionally > 70% ?-? linked) tetrameric hemoglobin with high efficiency of oxygen delivery suitable for use in mammals without causing renal injury and vasoconstriction is provided. The dimeric form of hemoglobin is degenerated and purification processes are performed on red blood cells from whole blood. Controlled hypotonic lysis in an instant cytolysis apparatus prevents lysis of white blood cells. Nucleic acids from white blood cells and phospholipids impurities are not detected. Blocking of reactive sulfhydryl groups by a sulfhydryl reagent is performed in an oxygenated environment. Flowthrough column chromatography removes different plasma protein impurities. N-acetyl cysteine is added to the cross-linked tetrameric hemoglobin to maintain a low level of met-hemoglobin. The stabilized hemoglobin is preserved in an infusion bag with aluminum overwrap to prevent formation of inactive met-hemoglobin from oxygen intrusion. The product finds use in tissue oxygenation and cancer treatment.
Patent NZ-595313-A (NZ)
Title: The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
Inventor: DESAI NEIL P
IPC: A61K33/243
Filed: 2006-02-21
Abstract: Disclosed is the use of nanoparticles comprising rapamycin and a carrier protein for the manufacture of a medicament for the treatment of a proliferative disease in an individual. Also disclosed is the use of nanoparticles comprising a taxane and a carrier protein for the manufacture of a medicament for the treatment of a proliferative disease in an individual, wherein the medicament is formulated to provide a weekly dose of 100 to 150 milligrams per square meter of body surface, or 0.25 percent to 25 percent of its maximum tolerated dose following a traditional dosing regime.
Patent NZ-595885-A (NZ)
Title: Automatic injection device
Inventor: SHANG SHERWIN S
IPC: A61M5/20
Filed: 2010-04-29
Abstract: Disclosed is a syringe plunger formed of a polymeric material. The syringe plunger includes a pressurizer disposed at a proximal end, and a distal end bifurcated into a first plunger arm having a first conical surface and a second conical surface, and a second plunger arm having a first conical surface and a second conical surface. The distal end includes a first contact surface defined by the first conical surface of the first plunger arm and the first conical surface of the second plunger arm, the first contact surface configured to initially contact a firing engagement mechanism, the first contact surface disposed at a first angle of between about 40° and about 80° relative to a longitudinal axis of the syringe plunger.
Patent NZ-596844-A (NZ)
Title: Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
Inventor: AHMED SALAH U
IPC: A61F6/14
Filed: 2009-02-03
Abstract: 596844 Disclosed is the use of (a) a therapeutically effective amount of progesterone; (b) a polysiloxane elastomer; and (c) a pharmaceutically acceptable glycerol esters of a fatty acid, in the preparation of a medicament for the treatment of a patient needing embryo implantation and early pregnancy support, wherein said medicament is a monolithic intravaginal ring comprising said therapeutically effective amount of progesterone, said polysiloxane elastomer and said pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid, and wherein the polysiloxane elastomer is present in a concentration of about 55% to about 90% by total weight of the ring. Also disclosed is a monolithic intravaginal ring for supporting embryo implantation and early pregnancy in a patient in need thereof, the ring comprising: (a) about 5% to about 40% by weight of progesterone; (b) about 55% to about 90% by weight of polysiloxane elastomer; and (c) about 0.1% to about 10% by weight of a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid, wherein the progesterone is homogeneously dispersed in the elastomer.
Patent NZ-600321-A (NZ)
Title: A flexible pipe assembly for connecting to an underwater installation, wherein the pipe comprises a curved elbow portion which anchors to the bottom
Inventor: HOVDE GEIR OLAV
IPC: E21B17/01
Filed: 2010-11-30
Abstract: 600321 An assembly for connecting a flexible line (20) to an underwater installation (18) is disclosed. The line extends between the underwater installation and a surface installation. The flexible line includes a surface end, a bottom end (28), a contact portion (26) and a floating portion (24). The floating portion extends between the contact portion and the surface end. The contact portion includes an angled part (40) that divides the contact portion into a first part (36) and a second part (38). The angled part is moored to the bottom at an anchoring point (42).
Patent NZ-601675-A (NZ)
Title: Process for the acetylation of wood elements
Inventor: MAES MICHEL
IPC: C08G18/64
Filed: 2011-02-04
Abstract: ABSTRACT - 601675 The disclosure relates to a composite wood product containing acetylated wood elements having one of the following properties: (a) an average value in thickness swelling not exceeding 5% after subjection to 25 wet-dry/freeze-thaw cycles as described in Table II according to DIN EN 12467/12, (b) retaining an average value of at least 90% of its modulus of elasticity after subjection to 25 wet-dry/freeze-thaw cycles as described in Table II according to DIN EN 12467/12, (c) retaining an average value of at least 90% of its bending strength after subjection to 25 wet-dry/freeze-dry cycles as described in Table II according to DIN EN 12467/12, or (d) retaining at least 70% of its modulus of rupture after soaking for 48 hours in water at ambient temperature, wherein said composite wood product is obtained by a process, comprising acetylation of wood elements, wherein the elements are (a) treated with acetic anhydride at a temperature of 30°C to 190°C at a pressure of atmospheric to a gauge pressure of 1.5 MPa for up to 80 minutes and thereafter (b) heated with an inert gas which may be mixed with acetic anhydride or a mixture of acetic anhydride and acetic acid to a temperature of 150°C to 190°C at a gauge pressure of 0.1 to 0.5 MPa for a period of 5 to 300 minutes.
Patent NZ-601757-A (NZ)
Title: Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
Inventor: STAHL TRACEY LYNN
IPC: A23L33/00
Filed: 2010-03-22
Abstract: Disclosed is a microbial oil comprising a triacylglycerol fraction of at least about 10% by weight, wherein at least about 12% by weight of the fatty acids in the triacylglycerol fraction is eicosapentaenoic acid, wherein at least about 20% by weight of the fatty acids in the triacylglycerol fraction is docosahexaenoic acid, and wherein less than about 5% by weight of the fatty acids in the triacylglycerol fraction is arachidonic acid.
Patent NZ-601805-A (NZ)
Title: Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
Inventor: BANG KEUK CHAN
IPC: C07D417/12
Filed: 2011-01-14
Abstract: Disclosed is a method for preparing the tetrazole methanesulfonic acid salt of formula (I), which comprises the steps of: acylating the compound of formula (III) with the compound of formula (II) to obtain the compound of formula (IV); and adding methanesulfonic acid to the compound of formula (IV). Also disclosed is a compound of formula (II) and the method of preparing a compound of formula (II).
Patent NZ-607326-A (NZ)
Title: Means and methods for the detection of a predisposition of a female subject to recurrent pregnancy loss (rpl), preeclampsia (pe) and/or fetal growth restriction (fgr)
Inventor: MARKOV ARSENI
IPC: C12Q1/68
Filed: 2011-08-26
Abstract: Disclosed is a method for diagnosing or detecting a predisposition of a female subject to recurrent pregnancy loss (RPL), preeclampsia (PE) and/or fetal growth restriction (FGR), comprising examining the human annexin A5 (ANXA5) promoter in a sample obtained from the intended biological father or the biological father and to detect nucleotide exchanges therein, wherein the presence of the nucleotide exchanges defined in (i) and/or (ii) indicates a predisposition of said female subject to recurrent pregnancy loss (RPL), preeclampsia (PE) and/or fetal growth restriction (FGR).
Patent NZ-617142-A (NZ)
Title: Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
Inventor: GANDHI ANITA
IPC: G01N33/574
Filed: 2012-04-27
Abstract: Disclosed is a method of identifying a drug sensitive cancer patient in a group of cancer patients comprising: determining the expression level of cereblon (CRBN) in a biological sample of a cancer, which has been obtained from a cancer patient; predicting clinical response, monitoring clinical response, or monitoring patient compliance to dosing by a drug, based on the expression level of CRBN, wherein the cancer patients are diffuse large B-cell lymphoma patients; and wherein the drug is thalidomide, lenalidomide, pomalidomide or 3-(5-amino-2-methyl-4- oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, a stereoisomer thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Patent NZ-623265-A (NZ)
Title: Stilbenoid compounds as inhibitors for squamous carcinoma and hepatoma and uses thereof
Inventor: SHENG-CHU KUO
IPC: C07D319/06
Filed: 2014-04-01
Abstract: The disclosure relates to compounds of Formula I wherein R, R’, R1, R2 and R3 are as defined within the specification. The disclosure also relates to a pharmaceutical composition comprising these stilbenoid compounds and their use in treating squamous carcinoma and hepatoma. The disclosure also relates to a method of synthesis of these compounds. Examples of the compounds include: 4-(3,5-dimethoxystyryl)phenyl-3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate 3,4’-[2,2-bis(hydroxymethyl)propanoxy]-resveratrol 3,5-[2,2-bis(hydroxymethyl)propanoxy]-resveratrol 3,5-acetyl-4’-[2,2-bis(hydroxymethyl)propanoxy]-resveratrol 5-acetyl-3-methyl-4’-[2,2-bis(hydroxymethyl)propanoxy]-resveratrol 3,5-[2,2-bis(hydroxymethyl)propanoxy]-4’-methyl-resveratrol Pterostilbene D-ribonic acid diacetonide